Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EVMN Evommune

盘后交易 06-17 16:13:28 EDT

20.65

+0.60

+2.99%

盘后20.65

+0.000.00%

16:10 EDT

最高20.94	最低19.73	成交量60.04万
今开20.24	昨收20.05	日振幅6.03%
总市值7.44亿	流通市值1.94亿	总股本3,602万
成交额1,230万	换手率6.40%	流通股本937.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":20.65,"timestamp":1781726400000,"preClose":20.05,"halted":0,"volume":600357,"hourTrading":{"tag":"盘后","latestPrice":20.65,"preClose":20.65,"latestTime":"16:10 EDT","volume":2901,"amount":59882.288247,"timestamp":1781727005103,"change":0,"changeRate":0,"amplitude":0.009201},"delay":0,"changeRate":0.029925187032418844,"floatShares":9375000,"shares":36018400,"eps":-2.11,"marketStatus":"盘后交易","change":0.6,"latestTime":"06-17 16:13:28 EDT","open":20.24,"high":20.9399,"low":19.73,"amount":12296572.710057,"amplitude":0.060344,"askPrice":21,"askSize":1,"bidPrice":19.84,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-2.11,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781740800000},"marketStatusCode":4,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":20.05,"preHourTrading":{"tag":"盘前","latestPrice":20.0365,"preClose":20.08,"latestTime":"09:14 EDT","volume":171,"amount":3411.995148,"timestamp":1781702071195,"change":-0.0435,"changeRate":-0.002166,"amplitude":0.00879},"postHourTrading":{"tag":"盘后","latestPrice":20.65,"preClose":20.65,"latestTime":"16:10 EDT","volume":2901,"amount":59882.288247,"timestamp":1781727005103,"change":0,"changeRate":0,"amplitude":0.009201},"volumeRatio":1.141919,"optionData":{"bulkOrders":[{"symbol":"EVMN","call":false,"expireDate":1784260800000,"strike":"15.0","timestamp":1781709044307,"price":2.5,"volume":1700,"amount":425000,"type":"-"}]},"impliedVol":1.9937,"impliedVolPercentile":0.9487},"requestUrl":"/m/hq/s/EVMN/","defaultTab":"news","newsList":[{"id":"1149806861","title":"Evommune公司提交招股说明书：现有股东拟转售最多450万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149806861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149806861?lang=zh_cn&edition=full","pubTime":"2026-04-18 04:08","pubTimestamp":1776456494,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新备案文件，生物制药公司Evommune已正式提交招股说明书，披露公司现有股东计划转售最多450万股Evommune普通股。\n此次备案文件显示，本次股份转售不涉及公司新发行股份，所有拟出售股份均来自现有股东。该招股说明书的提交标志着股东已获得通过公开市场减持公司股份的资格。\n作为专注于炎症性疾病创新疗法开发的临床阶段生物技术企业，Evommune此次股东股份转售计划受到市场关注。文件未透露具体售股股东身份及股份出售时间安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617590756","title":"Evommune, Inc.盘中异动 快速下跌6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617590756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617590756?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:41","pubTimestamp":1772635288,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日22时41分，Evommune, Inc.股票出现异动，股价大幅下挫6.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Klotho Neurosciences, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Klotho Neurosciences, Inc.、Onconetix, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为38.04%、31.92%、23.82%，振幅较大的相关个股有Klotho Neurosciences, Inc.、Edesa Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为28.39%、20.67%、13.00%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224128a6a29a01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224128a6a29a01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614897402","title":"Evommune, Inc.盘中异动 快速下跌5.11%报25.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897402?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:48","pubTimestamp":1772203739,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日22时48分，Evommune, Inc.股票出现波动，股价急速下跌5.11%。截至发稿，该股报25.27美元/股，成交量6.4999万股，换手率0.21%，振幅8.30%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227224859a7274650&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227224859a7274650&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612019442","title":"Evommune, Inc.盘中异动 急速下跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612019442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612019442?lang=zh_cn&edition=full","pubTime":"2026-02-18 03:28","pubTimestamp":1771356532,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日03时28分，Evommune, Inc.股票出现异动，股价快速跳水5.23%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Polaryx Therapeutics, Inc.、Cibus, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Ensysce Biosciences, Inc.、Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.较为活跃，换手率分别为810.90%、101.69%、96.36%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Ensysce Biosciences, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为81.33%、74.28%、39.89%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611901796","title":"Evommune, Inc.盘中异动 大幅跳水5.09%报27.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611901796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611901796?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:32","pubTimestamp":1770906774,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时32分，Evommune, Inc.股票出现波动，股价快速跳水5.09%。截至发稿，该股报27.01美元/股，成交量2.4506万股，换手率0.08%，振幅2.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168920254","title":"Evommune公司：同时评估Evo301的潜在新增适应症，包括溃疡性结肠炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1168920254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168920254?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:32","pubTimestamp":1770726755,"startTime":"0","endTime":"0","summary":"Evommune公司正在对Evo301的潜在新增适应症展开评估，其中溃疡性结肠炎是重点考察方向之一。这一举措旨在拓宽该药物的应用范围，为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100113507","title":"Evommune公布Evo301治疗中重度特应性皮炎二期a期概念验证试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113507","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100113507?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:31","pubTimestamp":1770726682,"startTime":"0","endTime":"0","summary":"生物制药公司Evommune近日宣布，其研发的候选药物Evo301在中重度特应性皮炎患者中开展的二期a期概念验证试验获得积极顶线结果。\n该试验数据表明Evo301在主要疗效终点上表现出显著改善，验证了其治疗潜力。这项突破为后续临床开发奠定了坚实基础，有望为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evommune.com","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":-0.1252},{"period":"3month","weight":-0.1677},{"period":"6month","weight":0.3358},{"period":"1year","weight":0.2531},{"period":"ytd","weight":0.1711}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Evommune, Inc.是一家于2020年4月在特拉华州注册成立的公司，总部位于加利福尼亚州的帕洛阿尔托。该公司是一家临床阶段的生物技术公司，专注于针对慢性炎症疾病主要致病因素的创新治疗方案开发。其初步临床开发项目集中在慢性自发性荨麻疹、特应性皮炎和溃疡性结肠炎上。","exchange":"NYSE","name":"Evommune","nameEN":"Evommune"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Evommune,EVMN,Evommune股票,Evommune股票老虎,Evommune股票老虎国际,Evommune行情,Evommune股票行情,Evommune股价,Evommune股市,Evommune股票价格,Evommune股票交易,Evommune股票购买,Evommune股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evommune(EVMN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Evommune(EVMN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}